What is Adagrasib?

Adagrasib is a groundbreaking targeted therapy developed to treat certain cancers caused by a mutation in the KRAS G12C gene. This mutation is commonly found in non-small cell lung cancer (NSCLC) and some other solid tumors.

Adagrasib Tablets work by specifically targeting and inhibiting KRAS G12C, a protein that drives cancer growth in these patients. As a precision medicine, Adagrasib offers a more personalized approach to cancer treatment with fewer off-target effects compared to traditional chemotherapy.

Key Benefits of Adagrasib Tablets

✅ Precision Targeting: Directly blocks KRAS G12C mutation, slowing tumor progression.
✅ Oral Convenience: Easy-to-take tablet format for at-home use.
✅ Effective in Advanced Cancer: Especially beneficial for patients with advanced or metastatic NSCLC.
✅ Well-Tolerated: Compared to chemotherapy, Adagrasib offers a more targeted approach, minimizing unnecessary side effects.

Medical Uses of Adagrasib

• Non-Small Cell Lung Cancer (NSCLC): For patients with KRAS G12C-mutated advanced or metastatic NSCLC.
• Other Cancers: Being explored for colorectal cancer, pancreatic cancer, and other tumors with KRAS G12C mutations.
  

  Possible Side Effects

  Although Adagrasib is generally well-tolerated, some patients may experience:

  • Nausea and vomiting
  • Diarrhea
  • Fatigue
  • Liver enzyme elevation (regular monitoring recommended)
  • Decreased appetite
  • Cough or breathing issues (especially in lung cancer patients)

  Always follow up with your oncologist to monitor and manage side effects.

Disclaimer

RxLane provides information for educational purposes only. All trademarks, brands, and service marks are the property of their respective owners. RxLane does not offer medical advice. Please consult your doctor for appropriate diagnosis and treatment. This content is intended for wholesalers, doctors, hospitals, clinics, pharmacies, and medical institutions.